Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025
Article content
NEW YORK — Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus entrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented in a poster session at ISPOR 2025, the Professional Society for Health Economics and Outcomes Research's annual conference, taking place May 13-16, 2025 in Montreal, QC, Canada.
Article content
Article content
Presentation Overview:
Article content
Title: Taletrectinib vs Entrectinib in ROS1-Positive (ROS1+) Non-Small Cell Lung Cancer (NSCLC): A Matching-Adjusted Indirect Comparison (MAIC)
Presenter: Misako Nagasaka, M.D., Ph.D., Associate Professor – Division of Hematology and Oncology, UCI School of Medicine
Date: Wednesday, May 14
Session Time: 10:30 a.m. – 1:30 p.m. ET
Session: Poster Session 1
Presentation Number: CO151
Article content
The materials will be made available in the Publications section of Nuvation Bio's website after the presentation.
Article content
About Taletrectinib
Article content
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib is being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study.
Article content
Based on results of the TRUST-I and TRUST-II clinical studies, the U.S. FDA has accepted and granted Priority Review to Nuvation Bio's NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval) and assigned a PDUFA goal date of June 23, 2025. The U.S. FDA previously granted taletrectinib Breakthrough Therapy Designation for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs, and Orphan Drug Designation for the treatment of patients with ROS1+ NSCLC and other NSCLC indications. In January 2025, China's NMPA approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC.
Article content
About Nuvation Bio
Article content
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib, a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor for glioma; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor.
Article content
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).
Article content
Article content
Article content
Contacts
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
24 minutes ago
- CBC
Married couple behind new Dawson City pizza place living their dream with shared business
There's no shortage of eateries in Dawson City, Yukon and now Kurt's Pizza is the newest restaurant where a husband and wife duo say they're living their dream as newlyweds, opening a new business in Dawson City. Kurt MacPherson and Lindsay Kirk moved to Dawson from Saskatchewan in February for a new start somewhere they can spend more time together. "It was our intention to have a business that we can both work together, not be going in separate directions in order to have a life together. It's been perfect for us," Kirk said. Kurt's Pizza is a small mobile trailer located on Second Avenue beside the CIBC bank. The inside is just big enough for the pair to move around in. It's equipped with a fridge, a counter with cutting boards and a stone oven built by MacPherson the average day MacPherson takes orders, and works the oven, while Kirk tops the pizzas. Dawson City already has two pizza restaurants but MacPherson said the friendly competition just makes him work harder. "I think it's good for business if it keeps everybody on their toes," he said. "You don't get lazy kind of thing, you know?" He said it's all in good fun, and isn't trying to step on anyone's toes but simply adding his pizza to the mix of the town's options. MacPherson said they've only been living in Dawson a few months but he knows it's going to be their home for at least a while. He said he's already dreaming of plans to expand his establishment into a full eat-in restaurant to serve the community all year long.
CTV News
26 minutes ago
- CTV News
Canada focusing on peace, energy security and new partnerships at G7 meeting: Carney
Prime Minister Mark Carney holds a press conference on Parliament Hill in Ottawa on Friday, June 6, 2025. THE CANADIAN PRESS/Sean Kilpatrick OTTAWA — Prime Minister Mark Carney says the G7 leaders' summit later this month in Alberta will see Canada seeking agreements in three key areas. Carney released a statement today saying Canada's top priority will be strengthening global peace and security, which includes countering foreign interference and transnational crime, as well as improving responses to wildfires. To spur economic growth, the prime minster says he will focus on improving energy security by fortifying supply chains for critical minerals and accelerating the use of artificial intelligence. As well, Carney says Canada will try to generate jobs by securing partnerships that will open new markets and generate big investments in infrastructure. Meanwhile, Carney says other discussions will explore securing a lasting peace in Ukraine, and reaching out to partners beyond the G7 to 'build coalitions with reliable partners.' The meeting, to be held in Kananaskis, Alta., from June 15 to 17, is expected to bring together leaders from the United States, the United Kingdom, France, Germany, Japan and Italy. 'Canada has what the world wants and the values to which others aspire,' Carney said in the statement. 'The G7 leaders' summit in Kananaskis is a moment for Canada to work with reliable partners to meet challenges with unity, purpose, and force. Canada is ready to lead.' This report by The Canadian Press was first published June 7, 2025. The Canadian Press
CTV News
38 minutes ago
- CTV News
‘It filled me with fear': New Brunswicker warns others about tick bites
Every year, more parts of Canada are reporting a risk of ticks and tick-borne illnesses. Sarah Plowman on the reasons behind the spread.
